MarginsXMarginsX
Home › Markets › Health Care › HUMA

Humacyte Inc. (HUMA)

HUMA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.5403
-3.24% on the day
Market cap
$150.1M
Micro cap
Revenue · 2025
$2.0M
Prior year not contiguous
Net income · 2025
-$40.8M
-2003.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1818382/000181838226000004/0001818382-26-000004-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerHUMA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2020
SEC CIK0001818382
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$2.0M
Net income-$40.8M
Operating income-$108.1M
Net margin-2003.6%
Operating margin-5306.0%
Revenue growthNo prior-year revenue to compare
Cash$50.5M
Total assets$116.4M
P/E (computed)Net income was not positive
P/S (computed)73.6×

Warning signs

Cash runway
8.8 months
$64.5M cash at September 30, 2026
Share count, 1 year
+48.3%
2025-11-04 to 2026-11-10 · +168.2% over 3 years
Going-concern doubt
Yes
10-Q filed November 10, 2026
Insider net buying, 12 months
$49K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors raise substantial doubt about the Company's ability to continue as a going concern."
10-Q 2026-11-10
Cash and burn$64.5M cash; operating cash flow -$22.1M a quarter.Report 2026-09-30
Shares outstanding277,798,105 (2026-11-10); 187,271,321 a year earlier; 103,575,256 three years earlier.Cover page 2026-11-10
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-06-11
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-07-31
Delisting25-NSE filed25-NSE 2026-08-25
AuditorPricewaterhouseCoopers LLP, Raleigh, North Carolina, United StatesPCAOB Form AP 2026-04-08
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $90K, sold $41K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$1.0M-$15.5M-$15.0M$64.5M$36.8M$2.4M10-Q 2026-11-10
Q2 2026
2026-06-30
$406K-$36.8M-$22.1M$79.9M$36.3M$2.1M10-Q 2026-08-12
Q1 2026
2026-03-31
$495K-$17.6M-$25.1M$48.5M$35.9M$2.0M10-Q 2026-05-13
Q4 2025
2025-12-31
$467K-$24.8M-$26.1M$50.5M$35.4M$2.0M10-K 2026-03-27
Q3 2025
2025-09-30
$753K-$17.5M-$23.9M$19.5MNo debt tags$1.6M10-Q 2026-11-10
Q2 2025
2025-06-30
$301K-$37.7M-$26.4M$38.0MNo debt tags$818K10-Q 2026-08-12
Q1 2025
2025-03-31
$517K$39.1M-$28.6M$62.8MNo debt tags$517K10-Q 2026-05-13
Q4 2024
2024-12-31
$0-$20.9M-$26.6M$44.9M$0$010-K 2026-03-27

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-06-11
Latest annual report10-K2026-03-27
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-10
Latest proxyDEF 14A2026-04-28

Source: SEC EDGAR submissions feed, 506 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+24.6%
1 month+55.4%
3 months+1.5%
Year to date-41.9%
1 year-53.1%
From 52-week high-62.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
TARAProtara Therapeutics Inc.$2.38-5.93%$146.5M
STROSutro Biopharma Inc.$9.32-5.09%$154.7M
IPHAInnate Pharma S.A. ADS$1.41-1.06%$156.9M
IVVDInvivyd Inc.$0.5377-7.63%$158.5M
FATEFate Therapeutics Inc.$1.14-10.94%$138.6M
ENGNenGene Therapeutics Inc.$1.89-21.58%$126.7M
CRDLCardiol Therapeutics Inc. Class A Common Shares$0.9798-2.02%$125.1M
PALIPalisade Bio Inc.$1.03-8.04%$184.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier